-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$79.3345.51% Upside
MoonLake Immunotherapeutics Frequently Asked Questions
-
What analysts cover MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics has been rated by research analysts at H.C. Wainwright, Goldman Sachs, Needham in the past 90 days.